Crossmark

761 Pharmacokinetic and pharmacodynamic data from a phase 1 study of CI-8993 Anti-VISTA antibody in patients with advanced solid tumors

Crossref DOI link: https://doi.org/10.1136/jitc-2022-SITC2022.0761

Published Online: 2022-11-07

Published Print: 2022-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Noelle, Randolph

Johnson, Melissa

Rodon, Jordi

Zauderer, Marjorie

Lewis, Lionel

Severgnini, Mariano

Parker, Jefferson

Lane, Maureen

Roemeling, Reinhard von

Martin, Alex

Molloy, Michael

Martell, Robert

Dai, Tong
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04475523 at ClinicalTrials.gov

Documents that mention this clinical trial

761 Pharmacokinetic and pharmacodynamic data from a phase 1 study of CI-8993 Anti-VISTA antibody in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2022-sitc2022.0761

Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner
https://doi.org/10.1136/jitc-2021-003382

392 Phase 1 study of CI-8993 anti-VISTA antibody in patients with advanced solid tumor malignancies
https://doi.org/10.1136/jitc-2020-sitc2020.0392